secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001559053-22-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q1 net loss $36.3M; PRX012 gets Fast Track, Phase 1 started
--------------------------------------------------------------------

- Net loss of $36.3M ($0.78 per share) vs $36.7M loss ($0.91) in Q1 2021; revenue $1.2M.
- Cash and restricted cash $544.3M at quarter end; no debt; net cash used in ops/investing $37.4M.
- PRX012 initiated Phase 1 SAD study, received FDA Fast Track for Alzheimer's disease.
- R&D expense $27.3M (up 29% YoY) driven by birtamimab, PRX012, PRX005 programs.
- FY 2022 guidance: net cash outflow $120-132M, net loss $154-170M, year-end cash ~$454M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000021/0001559053-22-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905322000021/prta-20220505.htm
  HTML page:      https://secwatch.observer/filing/0001559053-22-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer